CureVac N.V. (CVAC)
| Market Cap | 2.74B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 187.12M |
| EPS (ttm) | -1.75 |
| PE Ratio | n/a |
| Forward PE | 9.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,901,517 |
| Open | 15.09 |
| Previous Close | 14.93 |
| Day's Range | 14.58 - 15.37 |
| 52-Week Range | 12.90 - 76.22 |
| Beta | n/a |
| Analysts | Sell |
| Price Target | 27.71 (+89.5%) |
| Earnings Date | Jul 28, 2022 |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncyt... [Read more...]
Financial Performance
In 2021, CureVac's revenue was 102.99 million, an increase of 110.74% compared to the previous year's 48.87 million. Losses were -411.72 million, 218.9% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for CVAC stock is "Sell." The 12-month stock price forecast is 27.71, which is an increase of 89.53% from the latest price.
News
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on ...
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery P...
Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer Frame's platform offer...
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe Ulrike Gnad-V...
Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the pos...
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the dis...
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milesto...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone - Initiated Phase 1 dose-esca...
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic...
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 V...
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron vari...
CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government
Shares of CureVac CVAC, -0.28% were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline GSK, +0.89% said they signed an agreement with the German government for pandemic prepare...
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million v...
CureVac begins Phase 1 clinical trial for new COVID-19 vaccine
Shares of CureVac CVAC, +0.47% were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's dev...
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
Phase 1 dose-escalation study started at clinical sites in the U.S. Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidat...
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
The RNA Printer (R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development ...
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study
CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generat...
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad infecti...
CureVac starts Phase 1 trial for experimental flu shot developed with GSK
Shares of CureVac CVAC, +5.06% gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza...
BofA Securities: there's hardly any upside in CureVac this year
Shares of CureVac N.V. (NASDAQ: CVAC) closed nearly 15% down on Friday after BofA Securities said there isn't much in the books this year for shareholders of the German biopharmaceutical company.
CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade. The post CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
BofA Downgrades CureVac On Limited 2022 Prospects
There is limited upside from CureVac BV's (NASDAQ:CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company's pipeline in 2022, according to BofA Securities. The CureVac Analyst: G...
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ri...
Why CureVac Stock Is Sinking Today
Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.
dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiedera...
CureVac Outlines Upcoming Catalysts For Vaccine Programs
Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs.
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review Nature publication of prom...